8-K: Henry Schein Reports Record Q3, Raises 2025 EPS Guidance

Henry Schein, Inc. announced record third-quarter 2025 financial results, raising its full-year non-GAAP diluted EPS and sales growth guidance, and detailing value creation initiatives.

Summary

• Reported record financial results for the third quarter ended September 27, 2025.
• Q3 2025 GAAP diluted EPS was $0.84, up from $0.78 in Q3 2024.
• Q3 2025 non-GAAP diluted EPS was $1.38, up from $1.22 in Q3 2024.
• Total net sales for Q3 2025 reached $3.3 billion, an increase of 5.2% compared to Q3 2024, driven by 3.3% internal sales growth, 0.7% from acquisitions, and 1.2% from foreign currency exchange.
• Global Distribution and Value-Added Services sales increased 4.8% (3.7% in constant currencies).
• Global Dental Distribution merchandise sales increased 4.6% (2.9% in constant currencies).
• Global Dental Distribution equipment sales increased 5.5% (3.4% in constant currencies), with strong growth in Germany and the U.S.
• Global Medical Distribution sales increased 4.7% (4.6% in constant currencies), reflecting growth in medical products, pharmaceuticals, and Home Solutions.
• Global Specialty Products sales increased 5.9% (3.9% in constant currencies), driven by dental implant and endodontics sales.
• Global Technology sales increased 9.7% (9.0% in constant currencies), due to accelerated adoption of cloud-based software and new revenue cycle management solutions.
• Adjusted EBITDA for Q3 2025 was $295 million, compared to $268 million in Q3 2024.
• Raised 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 (previously $4.80 to $4.94), representing 3% to 5% year-over-year growth.
• Raised 2025 total sales growth guidance to approximately 3% to 4% (previously 2% to 4%).
• Announced value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years.
• Approved an amendment to the Strategic Partnership Agreement giving KKR the right to increase its HSIC stock ownership up to 19.9% through open market purchases.
• Repurchased approximately 3.3 million shares of common stock for $229 million at an average price of $68.62 per share during Q3 2025, with $980 million remaining authorized for future repurchases.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive financial results, including record earnings and sales growth, coupled with raised full-year guidance. Strategic initiatives for operating income improvement and increased investor confidence from the KKR agreement further enhance the positive sentiment.

Positives

• Record financial results for the third quarter of 2025, with strong sales growth accelerating across all reportable segments.
• Q3 2025 GAAP diluted EPS increased to $0.84 from $0.78 in Q3 2024, a 7.7% increase.
• Q3 2025 non-GAAP diluted EPS increased to $1.38 from $1.22 in Q3 2024, a 13.1% increase.
• Total net sales grew 5.2% to $3.3 billion in Q3 2025, demonstrating solid internal sales growth (3.3%) and market share gains.
• Adjusted EBITDA for Q3 2025 increased to $295 million from $268 million in Q3 2024.
• Full-year 2025 non-GAAP diluted EPS guidance was raised to $4.88 to $4.96, indicating continued confidence in future performance.
• Full-year 2025 total sales growth guidance was raised to 3% to 4%.
• Value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years.
• The amendment to the Strategic Partnership Agreement allows KKR to increase its ownership up to 19.9%, signaling strong investor confidence.
• Successful execution of the BOLD+1 strategy and financial performance of high-growth, high-margin businesses are setting a foundation for strong future growth.

Risks

• Dependence on third parties for the manufacture, supply of products, raw materials, or purchased components.
• Risks relating to the achievement of strategic growth objectives, including anticipated results of restructuring and value creation initiatives.
• Risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025.
• Transitions in senior company leadership.
• Ability to develop or acquire and maintain and protect new products (particularly technology and specialty products) and services and utilize new technologies that achieve market acceptance with acceptable margins.
• Transitional challenges associated with acquisitions and joint ventures, including failure to achieve anticipated synergies/benefits and significant demands on operational, information systems, legal, regulatory, compliance, financial, and human resources functions.
• Certain provisions in governing documents that may discourage third-party acquisitions.
• Adverse changes in supplier rebates or other purchasing incentives.
• Risks related to the sale of corporate brand products.
• Risks related to activist investors.
• Security risks associated with information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident).
• Effects of a highly competitive and consolidating market, including competition from third-party online commerce sites.
• Political, economic, and regulatory influences on the health care industry.
• Risks from expansion of customer purchasing power and multi-tiered costing structures.
• Increases in shipping costs for products or other service issues with third-party shippers, and increases in fuel and energy costs.
• Changes in laws and policies governing manufacturing, development, and investment in territories and countries where business is conducted.
• General global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment, consumer confidence, sovereign debt levels, fluctuations in energy pricing, and the value of the U.S. dollar.
• Failure to comply with existing and future regulatory requirements, including those relating to health care, the EU Medical Device Regulation, health care fraud, and data privacy.
• Changes in tax legislation, tax rates, and availability of certain tax deductions.
• Risks related to product liability, intellectual property, and other claims.
• Risks associated with customs policies or legislative import restrictions.
• Risks associated with disease outbreaks, epidemics, pandemics (such as COVID-19), or similar widespread public health concerns and other natural or man-made disasters.
• Risks associated with global operations.
• The threat or outbreak of war (e.g., Ukraine, Israel-Gaza), terrorism, or public unrest.
• Changes to laws and policies governing foreign trade, tariffs, and sanctions or greater restrictions on imports and exports.
• Supply chain disruption.
• Litigation risks and new or unanticipated litigation developments.
• Dependence on senior management (including succession planning for the Chief Executive Officer), employee hiring and retention, increases in labor costs or health care costs, and relationships with customers, suppliers, and manufacturers.
• Disruptions in financial markets.

Future Outlook

Henry Schein raised its 2025 financial guidance, now expecting non-GAAP diluted EPS attributable to Henry Schein, Inc. to be between $4.88 and $4.96, reflecting year-over-year growth of 3% to 5%. Total sales growth for 2025 is projected to be approximately 3% to 4% over 2024. Adjusted EBITDA growth for 2025 is still expected to increase mid-single digits compared with 2024. The company anticipates over $200 million of operating income improvement over the next few years from value creation initiatives.

Management Comments

• Stanley M. Bergman, Chairman and CEO, stated, "We are pleased with our financial results for the third quarter, with sales growth accelerating in each of our reportable segments including solid market share gains in our distribution businesses as we are once again focused on driving growth now that the cyber incident is fully behind us."
• Mr. Bergman also noted, "This strong sales performance was a key driver of the underlying improvement in our operating income."
• Regarding strategic initiatives, Mr. Bergman commented, "Our successful execution of the BOLD+1 strategy, including the financial performance of our investments in high-growth, high-margin businesses, set the foundation for strong future growth."
• He added, "With continued input from KKR, we have made good progress on advancing the value creation initiatives we announced last quarter. Based on our first phase of work, we believe we have the opportunity to deliver over $200 million of improvements to operating income over the next few years."

Industry Context

Henry Schein, Inc. positions itself as the world's largest provider of health care solutions to office-based dental and medical practitioners. The strong sales performance across its Global Dental, Medical, Specialty Products, and Technology segments suggests robust demand within these healthcare sectors, potentially outpacing broader industry trends in some areas, especially with accelerated adoption of cloud-based software and new revenue cycle management solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking. However, Henry Schein's self-description as the 'world's largest provider of health care solutions to office-based dental and medical practitioners' implies a leading market position.

Corporate Governance

Legal Proceedings

• Non-GAAP adjustments include litigation settlements related to certain opioid-related lawsuits during Q3 2025 and YTD 2025.
• Non-GAAP adjustments also include a settlement at one of the businesses and YTD 2024 settlement amounts for litigation related to the October 2023 cyber incident.

Related Party Transactions

• Amendment to the Strategic Partnership Agreement with KKR, giving KKR the right to increase its HSIC stock ownership up to 19.9%.

Stakeholder Impact

• Shareholders: Positive impact due to record financial results, raised guidance, ongoing share repurchases, and increased confidence from KKR's potential increased ownership.
• Customers: Continued focus on improving operational success and clinical outcomes through Business, Clinical, Technology, and Supply Chain solutions.
• Employees (Team Schein Members): Continued strategic execution and value creation initiatives may impact operational structures, but the company emphasizes its network of over 25,000 Team Schein Members.
• Suppliers/Manufacturers: Continued dependence on third parties for product manufacturing and supply, indicating ongoing relationships.

Next Steps

• Host a conference call on November 4, 2025, at 8:00 a.m. Eastern time to discuss third-quarter 2025 financial results.
• Continue execution of the BOLD+1 strategy.
• Advance value creation initiatives to deliver over $200 million of operating income improvement over the next few years.
• KKR has the right to increase its HSIC stock ownership up to 19.9% through open market purchases.

Key Dates

Recommendation

The filing demonstrates robust financial performance with record Q3 results, significant year-over-year growth in both GAAP and non-GAAP EPS, and strong sales acceleration across all segments. The raised full-year guidance for both EPS and sales growth signals management's confidence in sustained momentum. Furthermore, the announced value creation initiatives targeting over $200 million in operating income improvement and the strategic partnership amendment allowing KKR to increase its stake up to 19.9% are strong indicators of future value creation and investor confidence. These factors collectively present a compelling investment case.

Keywords

Healthcare Solutions, Dental, Medical, Distribution, Technology, Financial Results, EPS Guidance, Operating Income, KKR, Strategic Partnership, Share Repurchase, Q3 2025